Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression
Open Access
- 26 June 2013
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 11 (9) , 1655-1662
Abstract
No abstract availableKeywords
Funding Information
- EUHASS
- Baxter
- Bayer
- Biotest
- CSL Behring
- Grifols
- LFB
- NovoNorsdisk
- Octapharma
- Pfizer
This publication has 25 references indexed in Scilit:
- Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studiesJournal of Thrombosis and Haemostasis, 2011
- Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatmentJournal of Thrombosis and Haemostasis, 2010
- The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia AHaemophilia, 2010
- Inhibitor development: patient‐determined risk factorsHaemophilia, 2010
- Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover studyJournal of Thrombosis and Haemostasis, 2009
- Clinical safety surveillance study of the safety and efficacy of long‐term home treatment with ReFacto® utilizing a computer‐aided diary: a Nordic multicentre studyHaemophilia, 2009
- Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia AHaemophilia, 2007
- Switching between full‐length and B‐domain‐deleted factor VIII and the risk of inhibitorsHaemophilia, 2006
- The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an updateHaemophilia, 2005
- Some Statistical Methods for Combining Experimental ResultsInternational Journal of Technology Assessment in Health Care, 1990